15th January 2013
Heptares announces deal with Cubist
Heptares Therapeutics has announced that it has signed an agreement with Cubist Pharmaceuticals, Inc (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs).
Read this article
3rd January 2013
eZono AG announces completion of $10m financing led by MVM
MVM Life Science Partners leads investment into portable tablet ultrasound platform and
novel needle guidance technology.
Read this article
22nd November 2012
Dr Bali Muralidhar Joins MVM Life Science Partners
Dr Muralidhar Joins MVM Life Science Partners' London office
Read this article
22nd October 2012
Dr Roger M. Perlmutter Joins Heptares’ Board of Directors
Welwyn Garden City, UK and Boston, MA, USA, 22 October 2012 – Heptares Therapeutics, the leading GPCR drug discovery company, has elected Dr Roger M. Perlmutter, the former Executive Vice President, Research and Development, at Amgen Inc. to its Board of Directors as a Non-executive Director.
Read this article
19th October 2012
FDA Advisory Committee Recommends Approval of Aegerion’s Drug - Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia
FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of
Homozygous Familial Hypercholesterolemia (HoFH)
Read this article
News Archive
Last 5 Articles | Next 5 Articles
10th January 2007Lead Compound Reduces LDL by 51% in Patients With a Severe Form of Hypercholesterolemia
Aegerion Pharmaceuticals announced last week the publication of positive results from a second Phase II clinical trial of its lead cholesterol-lowering compound AEGR-733 in the January 11, 2007 issue of the New England Journal of Medicine.
The results demonstrate that AEGR-733 reduced the levels of low-density lipoprotein (LDL) or “bad cholesterol” by a remarkable 51% in subjects with homozygous familial hypercholesterolemia (FH).
FH is a genetic condition characterized by dangerously high LDL-C levels.
AEGR-733 was also effective in reducing total cholesterol levels by 58%, triglyceride levels by 65%, and apolipoprotein B levels by 56%.
The results of this study suggest that AEGR-733 is a highly effective and potentially promising agent to treat these high-risk, hard-to-treat patients, for whom there are few effective treatment options.
It may also have applicability in a much broader population of patients who are not sufficiently clinically responsive to standard therapy or are intolerant of statins.
| Associated Links Visit Aegerion Pharmaceuticals, Inc. |
Downloads Full Press Release |